Steegen K, Bronze M, Papathanasopoulos M A, van Zyl G, Goedhals D, Van Vuuren C, Macleod W, Sanne I, Stevens W S, Carmona S C
Department of Molecular Medicine and Haematology.
National Health Laboratory Services.
J Infect Dis. 2016 Dec 15;214(12):1826-1830. doi: 10.1093/infdis/jiw491. Epub 2016 Oct 20.
Limited data exist on human immunodeficiency virus type 1 (HIV-1) resistance in patients who are not responding to protease inhibitor (PI)-based regimens in resource-limited settings. This study assessed resistance profiles in adults across South Africa who were not responding to PI-based regimens. pol sequencing was undertaken and submitted to the Stanford HIV Drug Resistance Database. At least 1 major PI mutation was detected in 16.4% of 350 participants. A total of 53.4% showed intermediate resistance to darunavir/ritonavir, whereas high-level resistance was not observed. Only 5.2% and 32.8% of participants showed high-level and intermediate resistance to etravirine, respectively. Although the prevalence of major PI mutations was within previously reported ranges, most patients will likely experience virological suppression during receipt of currently available South African third-line regimens.
在资源有限的环境中，关于对基于蛋白酶抑制剂（PI）方案无反应的患者的人类免疫缺陷病毒1型（HIV-1）耐药性的数据有限。本研究评估了南非各地对基于PI方案无反应的成年人的耐药谱。进行了pol测序并提交至斯坦福HIV耐药数据库。在350名参与者中，16.4%检测到至少1个主要PI突变。共有53.4%的人对达芦那韦/利托那韦表现出中度耐药，而未观察到高水平耐药。分别只有5.2%和32.8%的参与者对依曲韦林表现出高水平和中度耐药。尽管主要PI突变的流行率在先前报告的范围内，但大多数患者在接受目前可用的南非三线方案治疗期间可能会实现病毒学抑制。
